Plain-English translation of NCT04886401 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand why some patients with advanced non-small-cell lung cancer respond well to pembrolizumab immunotherapy while others do not. This study will analyze tumor tissue samples using advanced imaging technology to identify patterns that predict which patients will benefit from this treatment and which may experience side effects.
Although this medication has helped many lung cancer patients, it only works for some people—even among those whose tumors show signs they should respond. Doctors need better tools to predict ahead of time who will benefit, so they can make smarter treatment decisions and avoid unnecessary side effects.
You likely qualify if…
You likely don't qualify if…
This is a retrospective study, meaning researchers will review your past medical records and existing tumor tissue samples that were already collected during your treatment. You will not need to undergo new procedures or receive additional medication. The study team will analyze your tissue using specialized imaging technology to identify patterns linked to treatment response.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
France
Enrollment target
~50 participants
Started
April 2021
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Margaux GEIER, MD
CHRU BREST
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.